Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p <0.05). Women with LVH had a higher prevalence of concentric hypertrophy than men (46% vs 29%, p = 0.0003). Logistic regression analysis demonstrated that female gender (odds ratio [OR] 2.80, p <0.0001), age (OR 1.03 per year, p <0.001), hypertension (OR 2.30, p <0.001), diabetes (OR 1.62, p = 0.004), and previous MI (OR 1.96, p = 0.001) were independently associated with LVH. In conclusion, patients with NVAF have a high prevalence of LVH, which is related to female gender, older age, hypertension, and previous MI. These patients are at high thromboembolic risk and deserve a holistic approach to cardiovascular prevention.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am. J. Cardiol.

Title: The American journal of cardiology

Publisher: Elsevier BV

ISSN (Electronic): 1879-1913

ISSN (Print): 0002-9149

Publication date (Electronic): Sep 15 2015

Volume: 116

Issue: 6

Affiliations

[1 ] University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy. Electronic address: marco.proietti@uniroma1.it.

[2 ] Pulmonary Hypertension Center, Thorax Clinic, University of Heidelberg, Heidelberg, Germany.

[3 ] Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy.

[4 ] Internal Medicine, Angiology and Atherosclerosis, Department of Medicine, University of Perugia, Perugia, Italy.

[5 ] Biomedical Department of Internal Medicine, University of Palermo, Palermo, Italy.

[6 ] First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

[7 ] I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy.

[8 ] University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Article

Publisher Item ID: S0002-9149(15)01528-3

DOI: 10.1016/j.amjcard.2015.05.060

PubMed ID: 26183791

SO-VID: 71ec2da0-cdb4-4aa0-ac72-e031444bdddc

History

Data availability:

Comments

Comment on this article

scite_

Cited by 9

See all cited by